Recombinant Human Insulin-Like Growth Factor-1 Treatment: Prime Time or Timeout? [Commentary on "Recombinant Human Insulin Like Growth Factor-1 Treatment: Ready for Prime Time" by Bright GM, Mendoza JR, Rosenfeld RG, Endocrinol Metab Clin N Am 2009; 38:625-38]
- PMID: 20169131
- PMCID: PMC2821650
- DOI: 10.1155/2009/429684
Recombinant Human Insulin-Like Growth Factor-1 Treatment: Prime Time or Timeout? [Commentary on "Recombinant Human Insulin Like Growth Factor-1 Treatment: Ready for Prime Time" by Bright GM, Mendoza JR, Rosenfeld RG, Endocrinol Metab Clin N Am 2009; 38:625-38]
References
-
- Rosenbloom AL. Is there a role for recombinant insulin-like growth factor-I in the treatment of idiopathic short stature? The Lancet. 2006;368(9535):612–616. - PubMed
-
- Rosenthal S. Part I: clinical diagnosis of IGF-I deficiency. Pediatric Endocrinology Reviews. 2007;4(supplement 2):252–256. - PubMed
-
- Butler AA, Le Roith D. Control of growth by the somatropic axis: growth hormone and the insulin-like growth factors have related and independent roles. Annual Review of Physiology. 2001;63:141–164. - PubMed
-
- Fofanova-Gambetti OV, Hwa V, Kirsch S, et al. Three novel IGFALS gene mutations resulting in total ALS and severe circulating IGF-I/IGFBP-3 deficiency in children of different ethnic origins. Hormone Research. 2009;71(2):100–110. - PubMed
-
- Cohen P. Problems with reclassification of insulin-like growth factor I production and action disorders. Journal of Clinical Endocrinology and Metabolism. 2006;91(11):4235–4236. - PubMed
LinkOut - more resources
Full Text Sources
